Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Sep 5 2019

Full Issue

Jockeying For Top Spot At FDA Intensifies With Acting Commissioner, Texas Oncologist Emerging As Contenders

Supporters say there's no better man for the job than the one currently filling it -- acting FDA Chief Norman “Ned” Sharpless. But people familiar with the process say Stephen Hahn of the M.D. Anderson Cancer Center in Houston may have caught the Trump administration's eye.

The Washington Post: FDA’s Ned Sharpless Gets Endorsement For Job As Permanent Commissioner

The jockeying over who will be the next Food and Drug Administration commissioner intensified Tuesday when former agency heads and dozens of health groups urged the White House to nominate acting FDA chief Norman “Ned” Sharpless to become the agency’s permanent commissioner. Supporters of Sharpless sent two letters — one from four former FDA commissioners and the other from more than 50 cancer and other groups — to President Trump and Health and Human Services Secretary Alex Azar. The letters had the same message: The FDA needs a permanent commissioner, and Sharpless should be nominated and confirmed to lead the agency. (McGinley, 9/4)

The Wall Street Journal: Texas Doctor Stephen M. Hahn Is A Top Contender To Head FDA

Stephen M. Hahn, a senior executive and radiation oncologist at M.D. Anderson Cancer Center in Houston, has emerged as a leading candidate to be nominated by the Trump administration to become commissioner of the Food and Drug Administration, according to people familiar with the matter. Dr. Hahn, 59 years old, is chief of radiation oncology and chief medical executive at M.D. Anderson, a research and clinical hospital affiliated with the University of Texas. He didn’t respond to phone calls or an email seeking comment. (Burton, 9/4)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF